Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KIT neg PDGFRB over exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KIT neg PDGFRB over exp | breast cancer | no benefit | Imatinib | Phase II | Actionable | In a Phase II trial, Gleevec (imatinib mesylate) treatment demonstrated no clinical activity, resulted in no objective response (0/13) in patients with metastatic breast cancer demonstrating Pdgfrb overexpression and negative Kit expression (PMID: 18515258). | 18515258 |